Contact Us

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Urinary incontinence means losing control of bladder due to which there is an involuntary leakage of urine. In this condition, control over the urinary sphincter is weakened or completely lost and due to this, a person urinates even when they do not want to. This is a very common and often embarrassing problem for people. At the time of urination, muscles around urethra relax and let urine pass out of the body, however, in urinary incontinence, muscles around urethra do not work in the way they should, resulting in leak-out of urine. There are various type of incontinences such as stress (bladder is under pressure), urge (intense urge to pass urine), and overflow (chronic urinary retention). The severity of urinary incontinence varies as per health conditions such as urinary tract infection (UTI), constipation, and age group, as urinary incontinence is found more in geriatric population.  

The global urinary incontinence treatment drugs market is estimated to be valued at US$ 4,180.6 million in 2020 and is expected to exhibit a CAGR of 3.8% during the forecast period (2020-2027).

Figure 1. Global Urinary Incontinence Treatment Drugs Market Share (%) Analysis, By Region, 2020

Urinary Incontinence Treatment Drugs  | Coherent Market Insights

Increasing number of regulatory approval for drugs is driving growth of the global urinary incontinence treatment drugs market

For instance, in 2018, Astellas Pharma Inc. received the U.S. Food and Drug Administration approval for its supplemental new drug application (sNDA) for the use of mirabegron in combination with the muscarinic antagonist solifenacin succinate for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence.

For instance, in 2016, Cipla Limited = received Abbreviated New Drug Application (ANDA) for Darifenacin extended-release tablets from the U. S. Food and Drug Administration (FDA) for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

request-sample

Urinary Incontinence Treatment Drugs Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2020: US$ 4,180.6 Mn
Historical Data for: 2017 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 3.8% 2027 Value Projection: US$ 5,427.7 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Incontinence Type: Urge Incontinence, Stress Incontinence, Over-flow Incontinence, Mixed Incontinence, Other Type.
  • By Drug Class: Anticholinergic/Antispasmodic agents, Skeletal muscle Relaxants, Antidepressants, Alpha blockers, Topical estrogens, Others.
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Companies covered:

Johnson & Johnson, Pfizer Inc., Astellas Pharma, Inc., Allergan, Inc., Takeda Pharmaceutical Company Limited, Merck & Co., Inc., and Sanofi S.A. 

Growth Drivers:
  • Increasing number of regulatory approval of drugs
  • Increasing prevalence of urinary incontinence disease
Restraints & Challenges:
  • Unfavorable side effects

Urinary Incontinence Treatment Drugs Market- Restraints

Unfavorable side effects such as constipation, dry skin, dry eyes, and upset stomach, low efficacy of available drug and difficulty in disease diagnosis, and negligence about urinary incontinence disorders are the major restraining factors for the urinary incontinence treatment drugs market growth.

Urinary Incontinence Treatment Drugs Market– Regional Analysis

North America accounted for the largest share in the urinary incontinence treatment drugs market, owing to increasing prevalence of overactive bladder. For instance, according to Urology Care Foundation 2019 report, it is estimated that 30% of men and 40% of women in the U.S. live with overactive bladder (OVB).

Furthermore, Asia Pacific is expected to observe the fastest growth during the forecast period, owing to increasing approval of drugs by regulatory authorities. For instance, in September 2018, Kissei Pharmaceutical Co., Ltd. and KYORIN Holdings, Inc. jointly announced that KYORIN Pharmaceutical Co., Ltd., a wholly owned subsidiary of KYORIN Holdings, Inc., received approval from the Ministry of Health, Labour and Welfare for the treatment of overactive bladder in Japan.

Figure 2. Urinary Incontinence Treatment Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2027

Urinary Incontinence Treatment Drugs  | Coherent Market Insights

Urinary Incontinence Treatment Drugs Market- Competitive Landscape

Key players operating in the urinary incontinence treatment drugs market include Johnson & Johnson, Pfizer Inc., Astellas Pharma, Inc., Allergan, Inc., Takeda Pharmaceutical Company Limited, Merck & Co., Inc., and Sanofi S.A.

Urinary incontinence is considered to be the variety of abnormalities occurs in the urinary tract that results in to experiencing normal micturition. This leads to involuntary loss of bladder control. Approximately 40% of community-dwelling elderly and hospitalized patients are afflicted with this disorder and the remaining 60% of nursing home patients experience this disorder, and it is often the reason for their admittance. The causes of urinary incontinence are numerous and involves age-related changes in the bladder and urethra, including decline in outlet resistance in females and prostate enlargement in males.

In urinary incontinence, muscles around urethra do not work in the way they should, resulting in leak-out of urine. There are various types of incontinences such as stress (bladder is under pressure), urge (intense urge to pass urine), and overflow (chronic urinary retention). The severity of urinary incontinence varies as per health conditions such as urinary tract infection (UTI), constipation, and age group, as urinary incontinence is found more in geriatric population.

Market Dynamics

The urinary incontinence treatment drugs market is expected to drive the market growth during the forecast period, owing to increasing prevalence of urinary incontinence disease. For instance, according to American Urological Association (AUA) 2017 report, more than 200 million people worldwide were affected with stress urinary incontinence (SUI) in 2017, which can seriously affect the quality of life of both men and women. As a disease whose prevalence is related to advancing age, it affects more women than men with an approximate ratio of 3: 1.

Key features of the study:

  • This report provides in-depth analysis of the global urinary incontinence treatment drugs market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2020-2027, considering 2019 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global urinary incontinence treatment drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Johnson & Johnson, Pfizer Inc., Astellas Pharma, Inc., Allergan, Inc., Takeda Pharmaceutical Company Limited, Merck & Co., Inc., and Sanofi S.A.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to future product launches, government initiatives, technological upgradation, market expansion, and marketing tactics
  • The global urinary incontinence treatment drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers in the urinary incontinence treatment drugs market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Urinary Incontinence Treatment Drugs Market, By Incontinence Type:
    • Urge Incontinence
    • Stress Incontinence
    • Over-flow Incontinence
    • Mixed Incontinence
    • Other Type
  • Global Urinary Incontinence Treatment Drugs Market, By Drug Class:
    • Anticholinergic/Antispasmodic Agents
    • Skeletal Muscle Relaxants
    • Antidepressants
    • Alpha Blockers
    • Topical Estrogens
    • Others
  • Global Urinary Incontinence Treatment Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Urinary Incontinence Treatment Drugs Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Incontinence Type:
        • Urge Incontinence
        • Stress Incontinence
        • Over-flow Incontinence
        • Mixed Incontinence
        • Other Type
      • By Drug Class:
        • Anticholinergic/Antispasmodic Agents
        • Skeletal Muscle Relaxants
        • Antidepressants
        • Alpha Blockers
        • Topical Estrogens
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Incontinence Type:
        • Urge Incontinence
        • Stress Incontinence
        • Over-flow Incontinence
        • Mixed Incontinence
        • Other Type
      • By Drug Class:
        • Anticholinergic/Antispasmodic Agents
        • Skeletal Muscle Relaxants
        • Antidepressants
        • ALPHA Blockers
        • Topical Estrogens
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Incontinence Type:
        • Urge Incontinence
        • Stress Incontinence
        • Over-flow Incontinence
        • Mixed Incontinence
        • Other Type
      • By Drug Class:
        • Anticholinergic/Antispasmodic Agents
        • Skeletal Muscle Relaxants
        • Antidepressants
        • Alpha Blockers
        • Topical Estrogens
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Incontinence Type:
        • Urge Incontinence
        • Stress Incontinence
        • Over-flow Incontinence
        • Mixed Incontinence
        • Other Type
      • By Drug Class:
        • Anticholinergic/Antispasmodic Agents
        • Skeletal Muscle Relaxants
        • Antidepressants
        • Alpha Blockers
        • Topical Estrogens
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Incontinence Type:
        • Urge Incontinence
        • Stress Incontinence
        • Over-flow Incontinence
        • Mixed Incontinence
        • Other Type
      • By Drug Class:
        • Anticholinergic/Antispasmodic Agents
        • Skeletal Muscle Relaxants
        • Antidepressants
        • Alpha Blockers
        • Topical Estrogens
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
      • By Incontinence Type:
        • Urge Incontinence
        • Stress Incontinence
        • Over-flow Incontinence
        • Mixed Incontinence
        • Other Type
      • By Drug Class:
        • Anticholinergic/Antispasmodic Agents
        • Skeletal Muscle Relaxants
        • Antidepressants
        • Alpha Blockers
        • Topical Estrogens
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
  • Company Profiles
    • Johnson & Johnson
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Pfizer Inc.
    • Astellas Pharma, Inc.
    • Allergan, Inc.
    • Takeda Pharmaceutical Company Limited
    • Merck & Co., Inc.
    • Sanofi S.A.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Incontinence Type
      • Market Snippet, By Drug Class
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Key Developments
    • Regulatory Scenario
    • New Lunches and Approvals
    • Pipeline Analysis
    • PEST Analysis
    • Epidemiology
  4. Global Urinary Incontinence Treatment Drugs Market - Impact of Coronavirus (Covid-19) Pandemic
    • Supply side Analysis
    • Demand Side Analysis
    • Impact on Healthcare Industry
  5. Global Urinary Incontinence Treatment Drugs Market, By Incontinence Type, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Urge Incontinence
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Stress Incontinence
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Over-flow Incontinence
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Mixed Incontinence
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Other Type
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  6. Global Urinary Incontinence Treatment Drugs Market, By Drug  Class, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Anticholinergic/Antispasmodic Agents
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Skeletal Muscle Relaxants
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Antidepressants
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Alpha Blockers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Topical Estrogens
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  7. Global Urinary Incontinence Treatment Drugs Market, By Distribution Channel, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Online Pharmacies
      • Introduction
      • Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  8. Global Urinary Incontinence Treatment Drugs Market, By Region, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, By Region, 2017 – 2027
      • Regional Trends
    • North America
      • Market Size and Forecast, By Incontinence Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Incontinence Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Latin America
      • Market Size and Forecast, By Incontinence Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Asia Pacific
      • Market Size and Forecast, By Incontinence Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Incontinence Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Incontinence Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
  9. Competitive Landscape
    • Company Profiles
      • Johnson & Johnson
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Astellas Pharma, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Allergan, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Takeda Pharmaceutical Company Limited
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Merck & Co., Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Sanofi S.A.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
  10. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 35 market data tables and 36 figures on "Global Urinary Incontinence Treatment Drugs Market” - Forecast to 2027”

Frequently Asked Questions

The CAGR of the urinary incontinence treatment drugs market is expected to be 3.8% during the forecast period (2020-2027).
The market is estimated to be valued at US$ 4,180.6 million in 2020.
The prominent players in the market include Johnson & Johnson, Pfizer Inc., Astellas Pharma, Inc., Allergan, Inc., Takeda Pharmaceutical Company Limited, Merck & Co., Inc., and Sanofi S.A.
The market is expected to be valued at US$ 5,427.7 Mn in 2027.
North America is the major region in the market.
The increasing number of regulatory approval of drugs and increasing prevalence of urinary incontinence disease are expected to drive growth of the market.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner